Our Team

Brian Sullivan
CEO and Co-founder

Brian has over 25 years of experience founding and building successful technology companies. He was chairman and CEO of Sterilmed, a medical device company, from 2003 until its sale to Johnson & Johnson for $330 million in 2011. Previously he was co-founder and CEO of Recovery Engineering, a filtration company that he took public and subsequently sold to Proctor and Gamble for $265 million in 1999. He has received seven U.S. patents. He graduated magna cum laude with distinction from Harvard College with an A.B. degree in economics.

Lance Laing, PhD
Chief Science Officer and Co-founder

Lance’s career spans more than 20 years in drug discovery research and technology development. He received his doctorate in biophysics and biochemistry from Johns Hopkins University and completed a National Institutes of Health postdoctoral fellowship at Washington University Medical School. He has received 19 U.S. patents. His drug discovery research career began at Scriptgen/Anadys Pharmaceuticals (purchased by Novartis), where he worked under Professor Peter Kim, the recently retired president of Merck Research Laboratories. Most recently, Lance served as an executive director for an international drug discovery and development company.

Lance has built a world-class science team that includes drug discovery, cell signaling, high-throughput drug screening, molecular oncology and human primary cell culture scientists.

Vicky Hahne

Vicky has more than 20 years of financial leadership experience, including the past 10 years in the healthcare industry. Prior to joining Celcuity, Vicky served as Controller of Respiratory Technologies Inc., a medical device manufacturer. While at Respiratory Technologies, she played a key role in the due diligence process to sell the company to Koninklijke Philips. Prior to Respiratory Technologies, she served as Controller for Ability Network Inc., a healthcare information technology company. From September 2007 through June 2012, Vicky served as Controller of Sterilmed Inc., a medical device reprocessing company, where she played a key role in the sale of the company to Johnson & Johnson. Prior to these roles, Vicky held several senior financial positions at SimonDelivers Inc., including Chief Financial Officer. Vicky has extensive experience in early stage, high growth companies with responsibilities including financial controls and stewardship, financial analysis, mergers and acquisitions, building infrastructure, and systems. She received a Bachelor of Science degree in Finance and Accounting from Northern State University and received her CPA certificate in 1990.

Eric Lindquist

Eric has over 20 years of experience in the diagnostic and companion diagnostic industry. Prior to joining Celcuity, he was the Global Vice President of Oncology and Rare Disease at Natera, where he launched Signatera to the pharmaceutical industry. He previously served as the Global Vice President of Customer and Companion Diagnostics at Asuragen, a molecular testing company, and as the Director of Business Development and Alliances for Companion Diagnostics at Roche Diagnostics. Early in his career, he was a sales specialist for molecular and companion diagnostics at Abbott Laboratories. He also spent time at Johnson & Johnson’s Veridex division, where he managed co-development partnerships with pharmaceutical and diagnostic companies.

Igor Gorbatchevsky, MD
VP Clinical Development

Igor has over two decades of hands-on oncology drug development experience, including successful regulatory IND and NDA/BLA filings across several drug classes. Prior to joining Celcuity, Igor worked for MEI Pharma (MEI), an oncology focused biopharmaceutical company, where he was the VP of Clinical Development. MEI’s pipeline included zandelisib, an oral PI3K-delta inhibitor. He had previously served as the VP of Clinical Science at Iovance Biotherapeutics, as a Global Clinical Leader at Bayer Pharmaceuticals, and as a Senior Medical Director at Daiichi-Sankyo a global pharmaceutical company. At Bayer, his responsibilities included leadership of the Global Clinical Development Team for ALIQOPA (copanlisib), a pan-PI3K inhibitor approved by the FDA for treatment of patients with follicular lymphoma. Prior to joining industry, he was a practicing clinician treating a broad range of tumor types in adults and children. Igor received his medical training at Omsk State Medical Academy with specialty training in clinical immunology at Chelyabinsk State Medical Academy.

Jill Krause
VP Clinical Operations

Jill brings deep clinical operations expertise, including over nine years of experience managing and executing trials in breast cancer. Prior to joining Celcuity, Jill worked for Odonate Therapeutics, a developer of an oral chemotherapy to treat breast cancer, where she served as VP of Clinical Operations Quality as well as VP of Study Management and Medical Affairs. She also served in a variety of different clinical operations roles at Pfizer for over 10 years, where her experience included serving as the Project Manager responsible for initiating the pivotal PALOMA-3 study. She also led clinical operations teams at several clinical research organizations. Jill received her MBA and BA in Business Administration from Eastern Michigan University.

Arthur DeCillis, MD
Chief Medical Officer

Arthur has over 25 years of experience in oncology clinical research and drug development. Previously he was the Chief Medical Officer for Eleven Biotherapeutics (now known as Sesen Bio Inc.), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies. Prior to that, he was the Vice President of Clinical Research and Vice President of Medical Affairs at Exelixis, Inc., an oncology-focused biotechnology company. He also served as Executive Director of Oncology Development at Novartis and Group Director of Bristol-Myers Squibb. Arthur has been involved in the development of several commercialized oncology drugs, including SPRYCEL® (dasatinib), AFINITOR® (everolimus), FARYDAK® (panobinostat) and CABOMETYX® (cabozantinib). Arthur was a member of the National Surgical Adjuvant Breast and Bowel Project (NSABP), a National Cancer Institute clinical cooperative group at the University of Pittsburgh. He has served as a member of the American Society of Clinical Oncology working group on economic analysis in Phase 3 clinical trials and the National Cancer Institute Common Toxicity Criteria Review Committee. He holds an MD from the University of Rochester and completed an internal medicine residency at Medical College of Virginia, followed by a fellowship at the University of Pittsburgh.

John R. MacDonald, PhD
SVP of R&D

John has over 30 years of experience in all aspects of pharmaceutical drug development and licensing. He led the preclinical and clinical R&D efforts at MGI Pharma, an oncology-focused company, from 1996 through 2005, and served as a consultant through MGI’s acquisition by Eisai in 2008. Prior to MGI he worked in large pharma at Warner-Lambert (now Pfizer) and in academia as an NIH funded researcher at UC San Francisco. Since 2006 he has remained active in drug development as a consultant advising academic institutions, startup and small pharma companies as the founder of Ridge Road Consulting and as the acting CEO of PepTx, Inc., a University of Minnesota startup. Dr. MacDonald earned a PhD in Pharmacology and Toxicology from the University of Arizona.

Bernhard Lampert, PhD
Head of CMC

Bernhard has over 30 years of drug development experience in the pharmaceutical and biotech industries, including 10 years in large, fully integrated pharmaceutical companies, including Gilead and GSK. He is currently working as an independent pharmaceutical consultant covering analytics (including bioanalytics), formulation development, API and drug product manufacture, and CMC regulatory documentation. He received his PhD in Medicinal Chemistry from the University of Georgia in 1989. Bernhard has authored/co-authored publications in peer-reviewed journals and is the co-inventor on patents on the manufacture of antiviral drugs.

Marie DeGayner Kuker
Head of Regulatory

Marie is the founder and president of Kuker Regulatory Consulting, a consulting firm specializing in biopharmaceutical regulatory affairs and compliance. She has more than 35 years of experience in the pharmaceutical industry, most recently as head of global regulatory affairs for 3M Pharmaceuticals and Drug Delivery Systems before founding her consultancy in 2007. She received her B.S. degree in Pharmacy from the University of Minnesota. She is Regulatory Affairs Certified and an appointed Fellow of the Regulatory Affairs Professionals Society. She is an Executive in Residence at the Technology Commercialization Discovery Launchpad at the University of Minnesota and Adjunct Assistant Professor in the Center for Orphan Drug Research, Department of Experimental and Clinical Pharmacology. She also teaches drug/device regulatory affairs in a Masters of Science program at St. Cloud State University.